CRISPR Therapeutics (CRSP) has seen its shares rise 7.05% as it strengthens its financial position despite ongoing losses. The biotech firm ended 2025 with nearly $2 billion in cash and equivalents, providing a solid buffer as it looks to expand sales of its approved gene-editing therapy, Casgevy. This one-time treatment for sickle cell disease and beta thalassemia generated $116 million in sales last year, with a notable acceleration in the fourth quarter.
While Casgevy’s high price tag of $2.2 million limits its market reach, CRISPR is actively developing five additional therapies, including promising candidates for cardiovascular diseases and cancers. The company’s robust cash reserves allow it to navigate the lengthy approval processes for these therapies, which could significantly broaden its market potential.
For investors, CRISPR’s strong cash position and advancing pipeline present a compelling case for future growth, particularly as gene-editing technologies continue to evolve and expand into larger patient populations.
Source: fool.com